Zhao et al. [17] showed that PCK2 knockdown reduced the tumor-initiating ability of prostate cancer (PCa) cells in the in vivo xenograft models and that the increased PCK2 level was associated with more aggressive tumors and lower survival rates for PCa patients. This evidence concerns the gene PCK2 and prostate carcinoma.